Details:
SAN903 was administrated daily during unilateral urinary obstruction the total fibrotic area was reduced by up to 43% (p>0.0001). SAN903 was well tolerated at all doses.
Lead Product(s): SAN903
Therapeutic Area: Nephrology Product Name: SAN903
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Arhus
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022